Market Overview

Establishment Labs announces transition to a Direct Sales Force in the United Kingdom

Share:

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market, announced today that it is transitioning, effective October 1, 2018, to a direct sales force in the United Kingdom.

In the United Kingdom, Establishment Labs previously employed a hybrid sales model that included both a distributor and direct sales strategy, but will now operate entirely through its own sales force to support the anticipated growth in this market. A direct sales model allows the company to fully engage with plastic surgeons, have total control over the sales and marketing process, and better manage the inventory needs of larger accounts.

"Our investment in a full, direct sales force operation in the United Kingdom demonstrates our commitment to this key market," said chief executive officer Juan José Chacón-Quirós. "Along with geographic expansion, direct sales efforts are a key growth driver for Establishment Labs, and this strategic move will support our growth in Europe. We have implemented similar strategies in other key markets, including Brazil and Sweden, and hope to do so again in the future."

The company currently sells in over 60 countries, with a direct sales force strategy in Brazil, France, Sweden, Denmark, and Norway. Establishment Labs is also working to convert its Austria business into a direct sales model, with an anticipated launch date of early 2019.

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ:ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 60 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA to initiate the Motiva Implant® clinical trial in the United States. In addition to Motiva Implants®, Establishment Labs' product and technologies portfolio includes Divina® 3D Simulation System, Puregraft, and MotivaImage® Centers.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "would," "may" or other similar expressions in this press release, and includes statements related to the expected growth in sales of Motiva Implants, product development, and the PMA clinical trial currently being conducted to obtain approval of Motiva Implants in the U.S. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control. Although we believe that our assumptions are reasonable, they are not guarantees of future performance, and some will inevitably prove to be incorrect. As a result, our actual future results may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the Company's Form S-1, Form 10-Q and other filings made by the Company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

Investor Relations and Media Contact
Kaitlyn Rawlett
Weber Shandwick
krawlett@webershandwick.com

EL Logo.jpg

View Comments and Join the Discussion!